Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new clinical data from its ongoing Phase 2 clinical trial evaluating evofosfamide ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Management Comments

Threshold Announces Clinical Update on Evofosfamide in Relapsed/Refractory Multiple Myeloma to Be Presented at ASCO 2015May 13, 2015 5:05 PM